ARKANSAS CHILDRENS HOSPITAL

Type: Teaching hospital
Where: Little Rock, AR
Medicare CCN: 043300
Received: $373,315 in 80 records, 2020 ($20,676 general, $352,638 research)
Source: CMS Open Payments search ↗

On this site

Nonprofit: ARKANSAS CHILDRENS HOSPITAL Fuzzy (name and state)

By year

Program year	Kind	Records	Amount
2020	General payment	11	$20,676
2020	Research payment	69	$352,638

By company

Company	Records	Amount	Years
JAZZ PHARMACEUTICALS INC.	1	$127,029	2020
Amgen Inc.	1	$116,899	2020
Merck Sharp & Dohme LLC	47	$33,577	2020
Grace Medical, Inc.	2	$16,536	2020
Stryker Corporation	3	$16,029	2020
Allergan, Inc.	5	$15,997	2020
B. Braun Medical Inc.	3	$15,353	2020
AMAG Pharmaceuticals, Inc.	2	$9,900	2020
UCB GmbH	2	$7,106	2020
E.R. Squibb & Sons, L.L.C.	1	$5,160	2020
Abbott Laboratories	3	$3,223	2020
UCB Biosciences Inc.	1	$2,967	2020
PFIZER INC.	3	$1,008	2020
Novartis Pharmaceuticals Corporation	1	$938	2020
Agios Pharmaceuticals, Inc.	1	$914	2020
Oticon Medical, LLC	1	$301	2020
LEICA MICROSYSTEMS INC.	2	$218	2020
Siemens Medical Solutions USA, Inc.	1	$154	2020

By nature of payment

Nature	Records	Amount
Research payment	69	$352,638
Gift	5	$16,247
Compensation for services other than consulting, including serving as faculty or as a speaker at a v	3	$3,223
Education	2	$1,051
Charitable Contribution	1	$154

Records

Date	Company	Amount	Nature	Form	Product	Study	Year
2020-12-31	Stryker Corporation	$12,196	Gift	Cash or cash equivalent	NONE Device, NONE		2020
2020-12-31	Stryker Corporation	$3,559	Gift	Cash or cash equivalent	NONE Device, NONE		2020
2020-12-31	Stryker Corporation	$272	Gift	Cash or cash equivalent	NONE Device, NONE		2020
2020-12-31	Siemens Medical Solutions USA, Inc.	$154	Charitable Contribution	In-kind items and services			2020
2020-11-16	UCB GmbH	$2,500	Research payment	Cash or cash equivalent	Cimzia Drug, Immunology	PHASE 3, MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN CHIL	2020
2020-11-11	PFIZER INC.	$420	Research payment	In-kind items and services	PRECEDEX Drug, SEDATIVE	A PHASE 4 RANDOMIZED DOUBLEBLIND DOSERANGING STUDY OF THE EFFICACY SAFETY AND PKPD OF DEXMEDETOMIDINE DEX WHEN USED WITH	2020
2020-11-09	Merck Sharp & Dohme LLC	$31	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-11-09	Merck Sharp & Dohme LLC	$31	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-11-09	Merck Sharp & Dohme LLC	$31	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-11-09	Merck Sharp & Dohme LLC	$31	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-11-09	Merck Sharp & Dohme LLC	$24	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-11-09	Merck Sharp & Dohme LLC	$24	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-11-09	Merck Sharp & Dohme LLC	$24	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-11-09	Merck Sharp & Dohme LLC	$24	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-11-09	Merck Sharp & Dohme LLC	$24	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-11-09	Merck Sharp & Dohme LLC	$24	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-11-09	Merck Sharp & Dohme LLC	$19	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-11-09	Merck Sharp & Dohme LLC	$19	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-11-09	Merck Sharp & Dohme LLC	$19	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-11-09	Merck Sharp & Dohme LLC	$19	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-11-09	Merck Sharp & Dohme LLC	$19	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-11-09	Merck Sharp & Dohme LLC	$19	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-11-09	Merck Sharp & Dohme LLC	$19	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-11-09	Merck Sharp & Dohme LLC	$19	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-11-09	Merck Sharp & Dohme LLC	$19	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-11-09	Merck Sharp & Dohme LLC	$10	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-11-09	Merck Sharp & Dohme LLC	$5	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-11-09	Merck Sharp & Dohme LLC	$4	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-11-09	Merck Sharp & Dohme LLC	$2	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-11-09	Merck Sharp & Dohme LLC	$1	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-10-23	Abbott Laboratories	$223	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2020
2020-10-09	PFIZER INC.	$168	Research payment	In-kind items and services	PRECEDEX Drug, SEDATIVE	A PHASE 4 RANDOMIZED DOUBLEBLIND DOSERANGING STUDY OF THE EFFICACY SAFETY AND PKPD OF DEXMEDETOMIDINE DEX WHEN USED WITH	2020
2020-09-21	UCB GmbH	$4,606	Research payment	Cash or cash equivalent	Cimzia Drug, Immunology	PHASE 3, MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN CHIL	2020
2020-09-02	JAZZ PHARMACEUTICALS INC.	$127,029	Research payment	In-kind items and services	VYXEOS Drug, HEMATOLOGY/ONCOLOGY	A STUDY TO COMPARE STANDARD CHEMOTHERAPY TO THERAPY WITH CPX-351 AND/OR GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED A	2020
2020-08-19	Novartis Pharmaceuticals Corporation	$938	Research payment	In-kind items and services	ADAKVEO Biological, HEMATOLOGY	A MULTICENTER RETROSPECTIVE NON INTERVENTIONAL FOLLOW UP STUDY IN PATIENTS WITH SICKLE CELL PAIN CRISIS WHO PREVIOUSLY P	2020
2020-07-24	Merck Sharp & Dohme LLC	$13,055	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-07-14	Grace Medical, Inc.	$9,306	Research payment	Cash or cash equivalent		TYMPANOSEAL	2020
2020-07-14	Grace Medical, Inc.	$7,229	Research payment	Cash or cash equivalent		TYMPANOSEAL	2020
2020-07-09	Merck Sharp & Dohme LLC	$31	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-07-09	Merck Sharp & Dohme LLC	$24	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-07-09	Merck Sharp & Dohme LLC	$24	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-07-09	Merck Sharp & Dohme LLC	$24	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-07-09	Merck Sharp & Dohme LLC	$20	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-07-09	Merck Sharp & Dohme LLC	$19	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-07-09	Merck Sharp & Dohme LLC	$19	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-07-09	Merck Sharp & Dohme LLC	$19	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-07-09	Merck Sharp & Dohme LLC	$19	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-07-09	Merck Sharp & Dohme LLC	$10	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-07-09	Merck Sharp & Dohme LLC	$7	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-07-09	Merck Sharp & Dohme LLC	$5	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-07-09	Merck Sharp & Dohme LLC	$5	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-07-09	Merck Sharp & Dohme LLC	$4	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-07-09	Merck Sharp & Dohme LLC	$3	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-07-09	Merck Sharp & Dohme LLC	$2	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-07-09	Merck Sharp & Dohme LLC	$2	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-07-09	Merck Sharp & Dohme LLC	$1	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-07-09	Merck Sharp & Dohme LLC	$0	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-07-01	Merck Sharp & Dohme LLC	$13,055	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly	2020
2020-06-29	PFIZER INC.	$420	Research payment	In-kind items and services	PRECEDEX Drug, SEDATIVE	A PHASE 4 RANDOMIZED DOUBLEBLIND DOSERANGING STUDY OF THE EFFICACY SAFETY AND PKPD OF DEXMEDETOMIDINE DEX WHEN USED WITH	2020
2020-06-08	UCB Biosciences Inc.	$2,967	Research payment	Cash or cash equivalent	Vimpat Drug, Neurology	A MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF INTRAVENOUS LACOSAMIDE IN CHILDREN 1 MONTH	2020
2020-05-27	Amgen Inc.	$116,899	Research payment	In-kind items and services	Kyprolis Drug, Oncology	[POETIC] Phase I study of Carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed and	2020
2020-04-29	AMAG Pharmaceuticals, Inc.	$6,000	Research payment	Cash or cash equivalent	FERAHEME Drug, PARENTERAL IRON REPLACEMENT	A PHASE 3, RANDOMIZED, OPEN-LABEL MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY AND PHARMACOKINETICS OF FERUMOXYTOL	2020
2020-04-29	AMAG Pharmaceuticals, Inc.	$3,900	Research payment	Cash or cash equivalent	FERAHEME Drug, PARENTERAL IRON REPLACEMENT	A PHASE 3, RANDOMIZED, OPEN-LABEL MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY AND PHARMACOKINETICS OF FERUMOXYTOL	2020
2020-04-21	Allergan, Inc.	$1,025	Research payment	Cash or cash equivalent	BOTOX Biological, UROLOGY	BOTOX IN THE TREATMENT OF URINARY INCONTINENCE DUE TO OVERACTIVE BLADDER IN PATIENTS 12 TO 17 YEARS OF AGE	2020
2020-04-17	Allergan, Inc.	$750	Education	Cash or cash equivalent			2020
2020-03-19	Allergan, Inc.	$10,150	Research payment	Cash or cash equivalent	DALVANCE Drug, ANTI-INFECTIVE	PHARMACOKINETICS OF A SINGLE-DOSE OF DALBAVANCIN IN PRETERM NEONATES TO INFANTS AGES 3 MONTHS WITH SUSPECTED OR CONFIRME	2020
2020-03-13	Agios Pharmaceuticals, Inc.	$914	Research payment	Cash or cash equivalent		Pyruvate Kinase Deficiency Global Longitudinal Registry	2020
2020-03-12	Allergan, Inc.	$3,000	Research payment	Cash or cash equivalent	ZENPEP Drug, CYSTIC FIBROSIS	LONG-TERM STUDY IN US CYSTIC FIBROSIS PATIENTS RECEIVING DIGESTIVE ENZYME SUPPLEMENTS TO ASSESS ANY NARROWING OF THE LAR	2020
2020-03-05	Oticon Medical, LLC	$301	Education (3 payments)	Cash or cash equivalent	PONTO BONE ANCHORED HEARING SYSTEM Device, Medical Device		2020
2020-02-27	E.R. Squibb & Sons, L.L.C.	$5,160	Research payment	Cash or cash equivalent	ORENCIA Biological, Immunology	An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis	2020
2020-02-26	Merck Sharp & Dohme LLC	$2,112	Research payment	Cash or cash equivalent	RECARBRIO Drug, INFECTIOUS DISEASE	A Phase 1b, Open label, Single dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of MK-7655A in Chil	2020
2020-02-26	Abbott Laboratories	$2,000	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2020
2020-02-26	Abbott Laboratories	$1,000	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2020
2020-02-06	LEICA MICROSYSTEMS INC.	$195	Gift	Cash or cash equivalent	N/A Device, CANCER DIAGNOSTICS		2020
2020-02-06	LEICA MICROSYSTEMS INC.	$22	Gift	Cash or cash equivalent	N/A Device, CANCER DIAGNOSTICS		2020
2020-01-23	Allergan, Inc.	$1,072	Research payment	Cash or cash equivalent	ZENPEP Drug, CYSTIC FIBROSIS	LONG-TERM STUDY IN US CYSTIC FIBROSIS PATIENTS RECEIVING DIGESTIVE ENZYME SUPPLEMENTS TO ASSESS ANY NARROWING OF THE LAR	2020
2020-01-10	Merck Sharp & Dohme LLC	$4,630	Research payment	Cash or cash equivalent	SIVEXTRO Drug, INFECTIOUS DISEASE	A Phase 1, Single-Dose Safety and Pharmacokinetic Study of Oral and IV Tedizolid Phosphate MK-1986 in Inpatients Under 2	2020
2020-01-02	B. Braun Medical Inc.	$10,397	Research payment	Cash or cash equivalent	CEFAZOLIN SODIUM Drug, INJECTIBLE DRUGS	SAFETY OF 1 G AND 2 G OF CEFAZOLIN IN PEDIATRIC SUBJECTS	2020
2020-01-02	B. Braun Medical Inc.	$2,706	Research payment	Cash or cash equivalent	CEFAZOLIN SODIUM Drug, INJECTIBLE DRUGS	SAFETY OF 1 G AND 2 G OF CEFAZOLIN IN PEDIATRIC SUBJECTS	2020
2020-01-02	B. Braun Medical Inc.	$2,250	Research payment	Cash or cash equivalent	CEFAZOLIN SODIUM Drug, INJECTIBLE DRUGS	SAFETY OF 1 G AND 2 G OF CEFAZOLIN IN PEDIATRIC SUBJECTS	2020

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.